{"id":"NCT00333359","sponsor":"XenoPort, Inc.","briefTitle":"XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome.","officialTitle":"An Open-Label, 52-Week Extension Study Assessing XP13512 Safety and Efficacy in Patients With Restless Legs Syndrome.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-06","primaryCompletion":"2008-12","completion":"2008-12","firstPosted":"2006-06-05","resultsPosted":"2011-06-23","lastUpdate":"2013-07-22"},"enrollment":581,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Restless Legs Syndrome"],"interventions":[{"type":"DRUG","name":"XP13512 (GEn)","otherNames":["GSK1838262","Gabapentin Enacarbil"]}],"arms":[{"label":"XP13512 (GEn)","type":"EXPERIMENTAL"}],"summary":"The primary objective of this trial is to assess the long-term safety and efficacy of XP13512 (Gabapentin Enacarbil) taken once daily for the treatment of patients suffering from Restless Legs Syndrome (RLS).","primaryOutcome":{"measure":"Change From Baseline in the International Restless Legs Syndrome Rating Scale (IRLS) at Week 52 Using Observed Case (OC)","timeFrame":"Baseline and Week 52","effectByArm":[{"arm":"Naïve; 1200 mg GEn","deltaMin":-16.3,"sd":8.23},{"arm":"Non-naïve; 1200 mg GEn","deltaMin":-17,"sd":8.2},{"arm":"All Participants; 1200 mg GEn","deltaMin":-16.8,"sd":8.21}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["21242741"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":197},"commonTop":["Somnolence","Dizziness","Headache","Fatigue","Nausea"]}}